Photon-Counting CT Offers Superior Imaging in Babies with Heart Defects

A new advanced form of CT imaging called photon-counting computed tomography (PCCT) offers better cardiovascular imaging quality at a similar radiation dose compared to dual-source CT (DSCT) in infants with suspected cardiac heart defects, according to a study published in Radiology a journal of the Radiological Society of North America.

Congenital heart defects are the leading cause of morbidity and mortality in the neonatal period, occurring in up to one percent of live births. Of those, approximately 25% are critical defects requiring surgical intervention within the first month after birth. A comprehensive assessment, including ultrasound, MRI and CT exams, is typically needed to plan for surgery and to create virtual and printed 3D reconstructions of the heart.

“Infants and neonates with suspected congenital heart defects are a technically challenging group of patients for any imaging method, including CT,” said Timm Dirrichs, M.D., senior physician and specialist in cardiothoracic radiology in the Department of Diagnostic and Interventional Radiology at RWTH Aachen University Hospital in Aachen, Germany. “There is a substantial clinical need to improve cardiac CT of this vulnerable group. It’s essential to carefully map the individual cardiac anatomy and possible routes of surgical intervention using the highest possible diagnostic standards.”

PCCT is an emerging imaging technique that counts the exact number and measures the energy of incoming x-ray photons. Compared with DSCT technology, PCCT offers higher image resolution and/or reduced radiation doses, which is of particular interest when imaging children. The PCCT technique has already been shown to improve cardiovascular CT imaging in adults. However, data on neonates and small children are lacking.

“Our aim was to evaluate the image quality of first-generation photon-counting CT for cardiac imaging in children with suspected cardiac heart defects compared with third-generation dual-source CT (DSCT) and to compare the respective radiation exposure,” Dr. Dirrichs said.

The research team analyzed existing clinical CT exams of 113 children who underwent contrast enhanced PCCT (30 infants), DSCT (83 infants) or both PCCT and DSCT (one infant) of the heart and thoracic aorta between January 2019 and October 2022. The study group consisted of 55 girls/58 boys (median age 66 days).

The researchers found that the PCCT images were sharper, with less image noise and greater contrast than DSCT images. The mean overall visual image quality ratings were higher for PCCT versus DSCT at a similar radiation dose. More than 97% of the PCCT images were at least diagnostic quality, compared to 77% of the DSCT images.

“In our study, none of the PCCT examinations exhibited a poor image quality, and only a few were of limited or moderate quality,” Dr. Dirrichs said.

He noted that of the DSCT images, almost one-quarter were of limited or non-diagnostic quality, and 40% were of moderate quality.

“PCCT is a promising method that may improve diagnostic image quality and efficiency compared to DSCT imaging,” Dr. Dirrichs said. “This higher efficiency can be used to reduce the radiation dose at a given image quality level or to improve image quality at a given radiation level.”

 

SourceRSNA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”